Bookmark and Share

ACTIMMUNE Drug Information Page

Updated 11/08/2010 12:12:41 AM

ProductSourceDateLinkData
ACTIMMUNEFDA2007-3-9ACTIMMUNE-FDA-2007-3-9FDA notified healthcare professionals of the early termination of the INSPIRE clinical study of Actimmune for idiopathic pulmonary fibrosis (IPF). The study was stopped because an interim analysis showed that patients with IPF who received Actimmune did not benefit. The trial compared survival in patients getting Actimmune or an inactive injection (placebo). An analysis showed that 14.5% of patients treated with Actimmune died as compared to 12.7% of patients treated with placebo. Actimmune is not approved by the FDA to treat IPF.

Joining this website will allow you to recieve emails about any pharmaceutial you are interested in or you can search for other pharmaceuticals on this website. Joining should only take 2 minutes.



Image of checkdrugs.com Logo
© Cardan Technologies Inc

This site is presented as an educational source only and you use it at your own risk. The information on this site is not a substitute for a visit with your doctor or pharmacist. Always talk to your doctor before changing medications or dosage, or if you experience any serious side effects.